L
2157
vs
H
Hang Seng (Hong Kong)
Over the past 12 months, Lepu Biopharma Co Ltd has outperformed Hang Seng (Hong Kong), delivering a return of +26% compared to the Hang Seng (Hong Kong)'s +12% growth.
Stocks Performance
2157 vs Hang Seng (Hong Kong)
Performance Gap
2157 vs Hang Seng (Hong Kong)
Performance By Year
2157 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Lepu Biopharma Co Ltd
Glance View
Lepu Biopharma Co., Ltd. operates as an an innovation-driven biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-02-23. The firm mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The firm's products are sold at home and abroad.